Abstract
Combination treatment with pegylated interferon plus ribavirin is the most effective therapy for patients with chronic hepatitis C virus (HCV); however, responses are less than optimal in some subpopulations of patients. Emerging insights are suggesting that viral kinetics can be used to predict response. The rapidity of response has been shown to be a more important predictor of sustained virologic response than the duration of therapy. In patients with HCV genotype 2 or 3, shorter durations of treatment might be sufficient in rapid responders and could minimize the risk of toxic effects. Weight-based dosing of ribavirin has emerged as another important consideration. This strategy seems to be most important for difficult-to-treat patients with HCV genotype 1 or advanced fibrosis, and for African-Americans, and is possibly important for patients who have genotype 3 and a high viral load. Re-treatment of nonresponders with interferon-based therapy has been associated with low rates of sustained virologic response. Consensus interferon might offer a new option for patients who do not achieve an early treatment response to standard or pegylated interferon plus ribavirin.
Key Points
-
Combination therapy with pegylated interferon and ribavirin is currently the most effective treatment for hepatitis C virus
-
Customizing treatment to specific patient populations can help optimize responses
-
Viral kinetics are likely to be used not only to predict nonresponse, but also to optimize responses and minimize toxic effects through adjustments to the duration of therapy
-
Weight-based dosing of ribavirin in combination with pegylated interferon seems to ameliorate the adverse impact of weight on rates of sustained virologic response in difficult-to-treat populations
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965
Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982
Hadziyannis SJ et al. (2004) Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355
Neumann AU et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103–107
Ferenci P et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425–433
Sanchez-Tapias JM et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastorenterology 131: 451–460
Hopkins S et al. (2006) Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 7: 248–254
Fuster D et al. (2006) Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther 11: 473–482
Dalgard O et al. (2004) Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 1260–1265
von Wagner M et al. (2005) Peginterferon-α2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522–527
Mangia A et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 325: 2609–2617
Shiffman ML (2006) Peginterferon alfa-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. Presented at 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26–30, Vienna, Austria
Berg T et al. (2006) Individualized treatment strategy with peginterferon alfa-2b (PEG-IFN ALFA) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients. Presented at: 41st Annual Meeting of the European Association for the Study of the Liver: 2006 April 26–30, Vienna, Austria
Jacobson IM et al. (2005) Weight-based ribavirin dosing increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology 42 (Suppl 1): 749A
Brown RS . Customizing treatment to patient populations. Presented at Treating Hepatitis C in Difficult-to-Treat Patients and Special Populations: 2006, 22 May, Los Angeles, CA
Brown RS et al. (2006) Differences in treatment outcomes to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. J Hepatol 44 (Suppl 2): S20
Afdhal N et al. (2006) The effect of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: results from the WIN-R trial. Gastroenterology 140 (Suppl 2): P120
Benhamou Y et al. (2006) The safety and efficacy of viramidine plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV: phase 3 results. J Hepatol 44 (Suppl 2): S273
HCV Meta-analysis Working Group et al. (2005) Efficacy of weight-based PEG-IFN alfa-2b vs. fixed dose PEG-IFN alfa-2a + ribavirin regimens in treatment-naïve chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinic sites. Hepatology 42 (Suppl 1): 671A
Ferenci P (2003) Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'? Dig Liver Dis 35: 601–606
Meyer-Wyss B et al. (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 13: 457–465
Muir AJ et al. (2004) Peginterferon alfa-2b ban ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265–2271
Jeffers LJ et al. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702–1708
Conjeevaram HS et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470–477
Jacobson I et al. (2004) Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans (AA) compared to flat dose ribavirin with peginterferon alfa-2B combination therapy. Hepatology 40 (Suppl 1): 125
Zeuzem S et al. (2004) Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40: 993–999
Teuber G et al. (2003) Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Gastroenterology 124 (Suppl 1): A768
Jacobson IM et al. (2003) Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results. Gastroenterology 124 (Suppl 1): A714
Sulkowski M et al. (2003) Pharmacokinetics, pharmacodynamics, and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving Peginterferon (40KD) alfa-2a (Pegasys). Gastroenterology 124 (Suppl 1): A702–703
Lawitz EJ et al. (2003) Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 124 (Suppl 1): A783–784
Gross JB et al. (2005) Double-dose peginterferon alfa-2b plus weight-based ribavirin for re-treatment of African-American non-responders with hepatitis C. Gastroenterology 123 (Suppl 2): A-684
Shiffman ML et al. (2004) Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015–1023
Leevy C et al. (2004) Interim results of a pilot study of the combination of type 1 (IFN Alfacon 1) and type 2 (IFN Gamma 1B) interferons in chronic hepatitis C patients who have failed to respond to peg-interferon alfa 2a plus ribavirin. Hepatology 40 (Suppl 4): 102A
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Brown, R. Customizing treatment to patient populations. Nat Rev Gastroenterol Hepatol 4 (Suppl 1), S3–S9 (2007). https://doi.org/10.1038/ncpgasthep0693
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0693